Novartis, a leading global innovative medicines company, has announced a planned $23 billion investment over 5 years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in the United States.
This commitment enables Novartis to expand on its current manufacturing, research and technology presence across the country with 10 facilities, including 7 brand new facilities, creating nearly 1,000 new jobs at Novartis and approximately 4,000 additional US jobs.
The production capacity will cover both active pharmaceutical ingredients (API) and biologics drug substance, as well as secondary production and packaging.
Over the next 5 years, Novartis will establish 1 biomedical research innovation hub in San Diego, CA, its second global R&D hub in the US; Build 4 new manufacturing facilities in soon-to-be-determined states, including 3 that will make biologics drug substances, drug products, device assembly and packaging, and 1 facility that will make chemical drug substances, oral solids dosage forms and packaging; Build 2 new radioligand therapy (RLT) manufacturing facilities in Florida and Texas; and expand 3 RLT manufacturing facilities in Indianapolis, IN, Millburn, NJ, and Carlsbad, CA
With these investments, Novartis will have manufacturing capacity in the US for all its core technology platforms, including small molecules and biologics. Novartis already manufactures its most innovative, advanced therapies in the US for patients in the US and around the world. With new manufacturing capacity, Novartis will be able to produce 100% of its key medicines end-to-end in the US, a significant increase from current levels.
